Research programme: PARP inhibitors - AstraZenecaAlternative Names: AZ 108; AZ 482; PARP 6 inhibitors - AstraZeneca
Latest Information Update: 03 Nov 2013
At a glance
- Originator AstraZeneca
- Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 20 Oct 2013 Preclinical trials in Cancer in USA (unspecified route)